Gendel
Coleraine
About Gendel
Gendel has developed a unique, proprietary platform technology for the localised delivery of biological molecules to target sites within the body. Biopharmaceuticals may be loaded into the body's own natural carrier system by a physical process and released at the target site in response to the application of non-invasive, low intensity ultrasound. Gendel's technology may be employed for the delivery of a range of biological payloads including antibodies, enzymes, peptides, olionucleotides and DNA as well as carrier peptides and gene therapy vectors.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $3.3M
- Last round: Series Unknown (May 2005)
Industries & Categories
Biopharma, Biotechnology, Health Care
Canonical: https://fsome.com/organization/gendel-668377 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.